New drug tested to combat deadly transplant complication

NCT ID NCT04543591

Ongoing Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether the drug ravulizumab can help control a dangerous blood clotting and organ damage condition (TMA) that sometimes occurs after a stem cell transplant. It will compare the drug plus standard care against a placebo plus standard care in about 148 participants aged 12 and older. The main goal is to see if the drug improves survival and prevents the condition from getting worse over 26 weeks of treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Tampa, Florida, 33612, United States
Research Site

Grosse Pointe Farms, Michigan, 48236, United States
Research Site

Durham, North Carolina, 27705, United States
Research Site

Pittsburgh, Pennsylvania, 15232, United States
Research Site

Seattle, Washington, 98109, United States
Research Site

Parkville, 3050, Australia
Research Site

Bruges, 8000, Belgium
Research Site

Brussels, 1200, Belgium
Research Site

Chênée, 4032, Belgium
Research Site

Yvoir, 5530, Belgium
Research Site

Cerqueira César, 05403-000, Brazil
Research Site

Florianópolis, 88034-000, Brazil
Research Site

Jaú, 17210-080, Brazil
Research Site

Porto Alegre, 90035-903, Brazil
Research Site

Porto Alegre, 90110-270, Brazil
Research Site

Rio de Janeiro, 20230-130, Brazil
Research Site

São José do Rio Preto, 15090-000, Brazil
Research Site

São Paulo, 05.403-010, Brazil
Research Site

Calgary, Alberta, T2N 4N1, Canada
Research Site

Suzhou, 215006, China
Research Site

Tianjin, 300020, China
Research Site

Angers, 49033, France
Research Site

La Tronche, 38043, France
Research Site

Nice, 06200, France
Research Site

Hamburg, 20246, Germany
Research Site

Ulm, 89081, Germany
Research Site

Athens, 12462, Greece
Research Site

Pátrai, 26504, Greece
Research Site

Thessaloniki, 57010, Greece
Research Site

Halfa, 31096, Israel
Research Site

Ramat Gan, 52621, Israel
Research Site

Roma, 00168, Italy
Research Site

Udine, 33100, Italy
Research Site

Akita, 010-8543, Japan
Research Site

Anjo, 446-8602, Japan
Research Site

Chiba, 260-0877, Japan
Research Site

Fukushima, 960-1295, Japan
Research Site

Isehara-shi, 259-1193, Japan
Research Site

Kurashiki-shi, 710-8602, Japan
Research Site

Minatoku, 105-8470, Japan
Research Site

Okayama, 700-8558, Japan
Research Site

Osaka, 545-8586, Japan
Research Site

Osakasayama-shi, 589-8511, Japan
Research Site

Sapporo, 060-8638, Japan
Research Site

Suita-shi, 565-0871, Japan
Research Site

Tsukuba, 305-8576, Japan
Research Site

Wakayama, 641-8510, Japan
Research Site

Groningen, 9713 GZ, Netherlands
Research Site

Goyang-si, 10408, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Barcelona, 08036, Spain
Research Site

Granada, 18014, Spain
Research Site

L'Hospitalet de Llobregat, 08908, Spain
Research Site

Madrid, 28007, Spain
Research Site

Madrid, 28034, Spain
Research Site

Madrid, 28040, Spain
Research Site

Madrid, 28046, Spain
Research Site

Málaga, 29010, Spain
Research Site

Pamplona, 31008, Spain
Research Site

Salamanca, 37007, Spain
Research Site

Seville, 41013, Spain
Research Site

Huddinge, 141 57, Sweden
Research Site

London, W12 0HS, United Kingdom
Research Site

Nottingham, NG5 1PB, United Kingdom

Conditions

Explore the condition pages connected to this study.

THROMBOTIC MICROANGIOPATHY